摘要
目的:评定HPLC法测定人血浆中奥硝唑浓度的不确定度。方法:对奥硝唑浓度测定过程中各影响因素,包括测定精密度、称量、标准溶液的配制、含药血浆的配制、血浆提取、仪器、标准曲线拟合等进行分析评定,计算各变量的不确定度和合成不确定度,最终计算扩展不确定度。结果:人血浆中低(0.5μg.mL-1)、中(5μg.mL-1)浓度奥硝唑的扩展不确定度分别为0.088μg.mL-1、0.324μg.mL-1(P=95%,k=2)。结论:HPLC法测定人血浆中奥硝唑浓度的不确定度主要由标准曲线拟合(尤其是低浓度)、标准溶液和血浆样品制备处理及仪器允差引入。
Objective:To evaluate uncertainty for the determination of ornidazole in human plasma by HPLC.Methods:It were analyzed that various factors affecting detection process,including repeatability,weighing,solution preparation,drug-spiked plasma preparation,solid phase extraction,HPLC error,calibration curve fitting,and so on.The expanded uncertainty was obtained by calculating each component of uncertainty and combined uncertainty.Results:The expand uncertainty of 0.5 μg·mL-1 and 5 μg·mL-1 was 0.088 μg·mL-1,0.324 μg·mL-1,respectively(P=95%,k=2).Conclusion:When determination of ornidazole in human plasma by HPLC,the uncertainty was mainly caused by the standard curve fitting(especially the low level of ornidazole),solution and plasma preparation,sample pretreatment and HPLC error.
出处
《药物分析杂志》
CAS
CSCD
北大核心
2011年第9期1797-1803,共7页
Chinese Journal of Pharmaceutical Analysis
基金
"十一五"国家科技重大专项"创新药物研究开发技术平台建设"
编号:2008ZX09312
关键词
药物分析
奥硝唑
生物样本
血药浓度
不确定度
高效液相色谱
pharmaceutical analysis
ornidazole
biological sample
plasma drug concentration
uncertainty
HPLC